Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent's (A) results for the fiscal third quarter reflect strong momentum in the pharma, and chemical & energy market.

Agilent (A) Q3 Earnings Surpass Estimates, Revenues Rise Y/Y

Illumina

Agilent Technologies proved its worth in FQ3 and was able to raise guidance as well, sending its shares higher as it continues to outperform Illumina.

Agilent Technologies Proves Its Worth VS Illumina

Agilent stock jumped Wednesday after putting together a strong quarterly beat that ignored the messy Covid dynamics plaguing other medtech companies. The post Agilent Puts Together Commanding Beat That Ignores Messy Medtech Dynamics appeared first on Investor's Business Daily.

Agilent Puts Together Commanding Beat That Ignores Messy Medtech Dynamics

BOSTON--(BUSINESS WIRE)--Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has partnered with Agilent, a global leader in life science, diagnostic and applied chemical markets. The two companies will collaborate on robust, scalable and reliable automation solutions for Mytide's BioFab2 platform, a technology suite that combines chemistry, robotics and machine learning to advance and accelerate peptide and peptide conjugate manufact

Mytide Therapeutics Partners with Agilent to Collaborate on Automation Solutions for Mytide's Next-generation Manufacturing Platform

Agilent Technologies, Inc. (NYSE:A ) Q3 2022 Earnings Conference Call August 16, 2022 4:30 PM ET Company Participants Parmeet Ahuja - Investor Relations Mike McMullen - President and Chief Executive Officer Bob McMahon - Senior Vice President and Chief Financial Officer Jacob Thaysen - President, Agilent Life Science and Applied Markets Group Sam Raha - President, Agilent Diagnostics and Genomics Group Padraig McDonnell - President, Agilent CrossLab Group Conference Call Participants Matt Sykes - Goldman Sachs Brandon Couillard - Jefferies Vijay Kumar - Evercore ISI Puneet Souda - SVB Rachel Vatnsdal - JPMorgan Mike Ryskin - Bank of America Josh Waldman - Cleveland Research Jack Meehan - Nephron Research Elizabeth Garcia - UBS Patrick Donnelly - Citi Tim Daley - Wells Fargo Operator Good afternoon. Thank you for attending today's Agilent Technologies Q3 ‘22 Earnings Call.

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q3 2022 Results - Earnings Call Transcript

Shares of Agilent Technologies Inc. A, -0.84% rose more than 5% in the extended session Tuesday after the maker of lab instruments and other components reported fiscal third-quarter results above Wall Street expectations and raised guidance for the year. Agilent said it earned $329 million, or $1.10 a share, in the quarter, compared with $264 million, or 86 cents a share, in the year-ago period.

Agilent stock rallies after quarterly beat, guidance increase for company

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the third quarter ended July 31, 2022, an increase of 8% compared to the third quarter of 2021 and up 13% on a core(1) basis. Third-quarter GAAP net income was $329 million, or $1.10 per share. This compares with $264 million, or 86 cents per share, in the third quarter of fiscal year 2021. Non-GAAP(2) net income was $401 million, or $1.34 per share during the quarter, compared

Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results

JENA, Germany--(BUSINESS WIRE)-- #SIRIUSScience--Bright Giant GmbH and Agilent Technologies are excited to announce their new product development collaboration, designed to enhance non-targeted metabolomics workflows using AI-based methods and empower scientists to make novel, impactful discoveries. This collaboration aims to combine Bright Giant's expertise in artificial intelligence solutions for small molecule research with Agilent's state-of-the-art mass spectrometry technology. Rapid, fully automated compo

Bright Giant GmbH and Agilent Technologies Announce Collaboration: Innovation for Identification

The company has been on a blazing-hot earnings streak, chaining together nine consecutive bottom-line beats.

Agilent Technologies Q3 Preview: Can the Earnings Streak Continue?

Agilent is set to report its fiscal Q3 earnings on August 16th. Shares have been under pressure all year amid broader macro headwinds, despite continued growth and earnings momentum.

Agilent Technologies: Turning Bullish Ahead Of Q3 Earnings

Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent Technologies (A) Reports Next Week: Wall Street Expects Earnings Growth

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization.

Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Professor Gerhardt Attard has been selected to receive a prestigious Agilent Thought Leader Award. Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London (UCL). Professor Attard is prominent for his innovative research and clinical trials using cutting-edge liquid biopsy technologies to identify biomarkers to monitor drug response and

Agilent Announces Thought Leader Award to Gerhardt Attard at University College London (UCL)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Stefanos Nikolaidis Ph.D. has received the Agilent 2022 Early Career Professor Award. Dr. Stefanos Nikolaidis is an Assistant Professor of Computer Science at the University of Southern California | USC Viterbi School of Engineering and leads the Interactive and Collaborative Autonomous Robotics Systems (ICAROS) lab. Dr. Chong Wing Yung, Associate Director of University Relations and External Research

Agilent 2022 Early Career Professor Award Presented to Stefanos Nikolaidis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today released its inaugural Environmental, Social, and Governance (ESG) report, including the company's first TCFD climate risk report; details on its commitment to reach net-zero greenhouse gas emissions by 2050; and progress on cultivating a diverse, inclusive, and engaged workforce. “The tenets of ESG have always been central to our mission, woven into the fabric of our business and a critical part of all that we stri

Agilent ESG Report Highlights Plans and Progress to Ensure Future Sustainable Growth

Cadence Design Systems

Global X Thematic Growth ETF

IQVIA Hlds

Invesco Select Growth ETF

Paychex

Synopsys

These are the best growth stocks to buy on the dip. A, CDNS, GXTG, IVSG, IQV, PAYX, and SNPS are poised to deliver impressive returns.

7 Growth Stocks to Buy on the Dip

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #EESummit22--Agilent Technologies Inc. (NYSE: A) today announced the company's Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award is sponsored by Environment+Energy Leader, a leading publisher of environmental, energy and sustainability best practices and research. Agilent's Certified Pre-Owned Instruments Program gives Agilent lab customers the option to trade in their used analytical inst

Agilent's Certified Pre-Owned Instruments Program Receives Environmental Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will release financial results for the third quarter of fiscal year 2022 after the stock market closes on Tuesday, Aug. 16. The company will host a live webcast of its investor conference call in listen-only mode on the same day. Details for the webcast: Date: Tuesday, Aug. 16, 2022. Time: 1:30 p.m. Pacific time. Access: A link to join the webcast will be provided in the Upcoming Events section of Agile

Agilent to Announce Third-Quarter Fiscal Year 2022 Financial Results August 16

NEW YORK--(BUSINESS WIRE)--Macquarie Asset Management's Green Investment Group (GIG) and Galehead Development (Galehead) today announced the close of an investment by GIG in Galehead, a leading US-based renewable energy development platform and trusted partner to global utilities, independent power producers and large US corporates for planning, managing and delivering renewable energy projects. Galehead is differentiated by its proprietary LandCommand® technology and specialized front-end deve

Macquarie Asset Management's Green Investment Group Completes Investment in Galehead Development

BURLINGAME, Calif. , July 11, 2022 /PRNewswire/ -- Halo Labs, a leading life science instrumentation company announced it has raised $6M in series C financing.

Halo Labs Completes $6M Series C Growth Financing

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that the FDA has approved a content uniformity (CU) method using the Agilent TRS100 Raman quantitative pharmaceutical analysis system. The submitting company, Teva Pharmaceutical Industries Ltd., is an Agilent Raman spectroscopy customer and global leader in generic and biopharmaceuticals. In 2021, the U.S. Food and Drug Administration (FDA) approved the company's CU method application, which was developed

Teva Uses the Agilent TRS100 to Achieve Regulatory Milestone for Content Uniformity Testing with the FDA

For investors who have been waiting to buy shares in Agilent, this is probably a good time to buy at least a starter position. For the last couple of years, Agilent had traded above what fundamentals justified, and now finally shares are priced to deliver very decent 8-9% returns.

Agilent Technologies Valuation Just Re-Entered 'Buy' Territory

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent (A) Down 5.5% Since Last Earnings Report: Can It Rebound?

Agilent Technologies, Inc. (NYSE:A ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 1:00 PM ET Company Participants Mike McMullen - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Matt Sykes Okay. Great. Welcome, everybody.

Agilent Technologies, Inc. (A) CEO Mike McMullen Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company's customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification, the gold standard in laboratory sustainability best practices. The Green Lab Certification from My Green Lab is recognized by the UN Race to Zero campaign as a key measure of progress for pharmaceutical and medical technology companies toward a zero-carbon future. It indicat

News for Agilent Technologies Stock (A)